London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I brought close to a million shares this morning for 0.3 just for the craic as genedrive was making me so much money and I read some of the comments you all posted. What the hell happened today? I near crapped my self when I looked at close of trade? Does this have more legs?
You purchased a million @0 30 and you want more profit !!!FFS
0 0 0
JOIN UP THE DOTS!!! Gla ;-)
Lamellar's Director appointed to the BoD of Motif, confirmed today....RTO into Lamellar looks like a dead cert imho....and Iclaprim, already cleared Phase 11 patient trials, and held up by the FDA at end of Phase 111 patient trials because of toxicity concerns from the intravenously administered drug, they wanted another Phase 111 trial that Motif couldn't afford, and now looks like Lamellar's nebulised inhaler technology's lead compound for the treatment of lung damage in Covid-19 patients could be Iclaprim, which can go straight into patient trials, cutting costs and time and saving Lamellar £10's of millions in its development. Gla holders Fill Ya Boots!!!:-)
1/5/19
Motif Bio Signs Agreement with Lamellar Biomedical
Evaluation of Iclaprim in Combination with LMS-611 for Cystic Fibrosis Lung Infections
Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company has signed an agreement with Lamellar Biomedical Limited (Lamellar) under which Motif Bio will conduct an in vivo pre-clinical study evaluating iclaprim in combination with Lamellar's patented LAMELLASOME(TM) technology.
Iclaprim has been granted U.S. orphan drug designation for Staphylococcus aureus pneumonia in patients with Cystic Fibrosis (CF). Lamellar's LAMELLASOME(TM) candidate LMS-611, which has mucokinetic (mucus clearing) properties, has demonstrated antibiotic potentiation (the enhancement of certain properties of antibiotics) and has European orphan drug designation for CF.
The companies believe that, based on pre-clinical data with the two individual components, the combination could be a promising potential treatment for lung infections in patients with CF.
Dr. Graham Lumsden, Chief Executive Officer of Motif Bio, said: "We have been looking for a way to optimise the development of iclaprim in patients with CF. We are excited about the preliminary data we have seen with Lamellar's technology and look forward to evaluating it in combination with iclaprim."
Dr. Alex McLean, Chief Executive Officer of Lamellar Biomedical, said: "CF is a key area of interest for Lamellar. We are delighted to announce this partnership with Motif Bio, which will evaluate the antibiotic potentiation properties of our LAMELLASOME(TM) technology in combination with iclaprim. This collaboration augments our own work in this orphan indication, which is focused on a novel nucleic acid-based therapeutic, as we strive to develop a range of highly effective treatment options for patients with CF."
sease areas, including orphan indications such as Staphylococcus aureus lung infections in patients with cystic fibrosis and in ophthalmology, as evidenced by recently announced collaborative agreements.
8/4/20
Lamellar Biomedical Launches Program Designed to Prevent the Severe Respiratory Effects of COVID-19, Using its Unique LAMELLASOMEâ„¢ Technology
....................
A LAMELLASOMEâ„¢ nebulised treatment used at the early stages of COVID-19, in hospital or the community, could reduce the damaging and often fatal inflammatory response known as Acute Respiratory Distress Syndrome (ARDS) seen in patients. This early intervention has the potential to inhibit fibroproliferative changes during ARDS, markedly reducing severity, mortality and lowering the significant burden placed on the healthcare system.
The time between onset of symptoms of SARS-CoV2 infection and progression to more severe clinical manifestations of COVID-19 such as viral pneumonia and ARDS, is thought to be between 5 – 8 days. Inhaled LAMELLASOME™ treatment administered during this period has the potential to halt or reduce the severity of the disease progression of COVID-19 patients to requiring scarce critical care resource.
Lamellar has strong pre-clinical evidence of inhaled LAMELLASOME™'s protective nature. In a large animal in‑vivo model of radiation-induced lung injury, designed to replicate the pathology found in the injured lung, which is representative of COVID-19 patient pathology, inhaled LAMELLASOME™ treatment protected lung cells and tissues from injury, pneumonitis and fibroproliferation/fibrosis at the alveolar/capillary membrane.
Dr Duncan Moore, Chairman of Lamellar, said: "In the past few weeks we have seen the terrible consequences COVID-19 can have on the respiratory function, particularly on vulnerable patient populations. We believe that that the inherent attributes of LAMELLASOMEâ„¢ are extremely well suited to be a potential approach to preventing the onset of the serious respiratory symptoms seen in COVID-19 patients. Lamellar is focused on treating complex lung disorders and we believe that our Lamellasome formulations could make an important difference to patients and healthcare providers globally."
Dr Nik Hirani, Reader in Respiratory Medicine and Associate Medical Director in Lothian and Former chair of NICE Thoracic Interstitial Lung Disease guideline committee, said: "Lamellar has very convincing data demonstrating strong in-vivo efficacy for Lamellasome formulations in a model relevant to pneumonitis, lung injury and ARDS. I have been following the development of LAMELLASOMEâ„¢ technology and its development as a respiratory therapeutic over the past few years, and I believe it has real potential to manage the inflammatory respiratory symptoms seen in patients infected with SARS-CoV2."
hTtps://www.ptcommunity.com/wire/lamellar-biomedical-launches-program-designed-prevent-severe-respiratory-effects-covid-19-us
sease areas, including orphan indications such as Staphylococcus aureus lung infections in patients with cystic fibrosis and in ophthalmology, as evidenced by recently announced collaborative agreements.
8/4/20
Lamellar Biomedical Launches Program Designed to Prevent the Severe Respiratory Effects of COVID-19, Using its Unique LAMELLASOMEâ„¢ Technology
....................
A LAMELLASOMEâ„¢ nebulised treatment used at the early stages of COVID-19, in hospital or the community, could reduce the damaging and often fatal inflammatory response known as Acute Respiratory Distress Syndrome (ARDS) seen in patients. This early intervention has the potential to inhibit fibroproliferative changes during ARDS, markedly reducing severity, mortality and lowering the significant burden placed on the healthcare system.
The time between onset of symptoms of SARS-CoV2 infection and progression to more severe clinical manifestations of COVID-19 such as viral pneumonia and ARDS, is thought to be between 5 – 8 days. Inhaled LAMELLASOME™ treatment administered during this period has the potential to halt or reduce the severity of the disease progression of COVID-19 patients to requiring scarce critical care resource.
Lamellar has strong pre-clinical evidence of inhaled LAMELLASOME™'s protective nature. In a large animal in‑vivo model of radiation-induced lung injury, designed to replicate the pathology found in the injured lung, which is representative of COVID-19 patient pathology, inhaled LAMELLASOME™ treatment protected lung cells and tissues from injury, pneumonitis and fibroproliferation/fibrosis at the alveolar/capillary membrane.
Dr Duncan Moore, Chairman of Lamellar, said: "In the past few weeks we have seen the terrible consequences COVID-19 can have on the respiratory function, particularly on vulnerable patient populations. We believe that that the inherent attributes of LAMELLASOMEâ„¢ are extremely well suited to be a potential approach to preventing the onset of the serious respiratory symptoms seen in COVID-19 patients. Lamellar is focused on treating complex lung disorders and we believe that our Lamellasome formulations could make an important difference to patients and healthcare providers globally."
Dr Nik Hirani, Reader in Respiratory Medicine and Associate Medical Director in Lothian and Former chair of NICE Thoracic Interstitial Lung Disease guideline committee, said: "Lamellar has very convincing data demonstrating strong in-vivo efficacy for Lamellasome formulations in a model relevant to pneumonitis, lung injury and ARDS. I have been following the development of LAMELLASOMEâ„¢ technology and its development as a respiratory therapeutic over the past few years, and I believe it has real potential to manage the inflammatory respiratory symptoms seen in patients infected with SARS-CoV2."
hTtps://www.ptcommunity.com/wire/lamellar-biomedical-launches-program-designed-prevent-severe-respiratory-effects-covid-19-us
Moneynutch I think you just did
The Company also has plans to develop iclaprim for hospital acquired bacterial pneumonia (HABP), including ventilator associated bacterial pneumonia (VABP), as there is a high unmet need for new therapies in this indication. A Phase 2 trial in patients with HABP has been successfully completed and a Phase 3 trial is being planned. Additionally, iclaprim has been granted orphan drug designation by the FDA for the treatment of Staphylococcus aureus lung infections in patients with cystic fibrosis and is in preclinical development for this indication
Well done Longrun, I wish I'd done the same. Can I have your Shares lol. Maybe I will buy tomorrow, but knowing my luck the Shares will go down. Good luck to you and to everyone else.